Myriad Genetics Inc (MYGN) is a publicly traded Healthcare sector company. As of July 23, 2026, MYGN trades at $5.70 with a market cap of $558.19M and a P/E ratio of -1.32. MYGN moved +0.88% today. Year to date, MYGN is -7.97%; over the trailing twelve months it is +23.31%. Its 52-week range spans $3.53 to $16.83. Analyst consensus is neutral with an average price target of $6.80. Rallies surfaces MYGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for MYGN combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $5.70 |
| Market Cap | $558.19M |
| P/E Ratio | -1.32 |
| EPS | $-4.29 |
| Dividend Yield | 0.00% |
| 52-Week High | $16.83 |
| 52-Week Low | $3.53 |
| Volume | 272.18K |
| Avg Volume | 0 |
| Revenue (TTM) | $829.00M |
| Net Income | $-399.90M |
| Gross Margin | 69.96% |
6 analysts cover MYGN: 0 strong buy, 2 buy, 3 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $6.80.